The European Alliance of Associations for Rheumatology (EULAR), formerly the European League Against Rheumatism, is a non-profit organization headquartered in Kilchberg, Switzerland. It represents people with rheumatic and musculoskeletal diseases (RMDs), health professionals in rheumatology, rheumatologists, researchers, and scientific societies across European nations. EULAR promotes education, research, prevention, treatment, and rehabilitation of RMDs, while advocating for improved care and quality of life for affected individuals. It organizes the annual European Congress of Rheumatology and facilitates the implementation of research advances into clinical practice.
Also known as European League Against Rheumatism.
Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
ALKIVIA+ 52‑week data show sustained Total Improvement Score gains; RHO+ shows maintained response after switch to biweekly dosing; safety consistent across indications.
